No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TWST240517C37500
- 9.92
- +3.62+57.46%
15min DelayClose May 17 15:59 ET
9.92High9.20Low
9.20Open6.30Pre Close11 Volume195 Open Interest37.50Strike Price10.56KTurnover2326.67%IV0.94%PremiumMay 17, 2024Expiry Date9.51Intrinsic Value100Multiplier0DDays to Expiry0.41Time Value100Contract SizeAmericanOptions Type0.9025Delta0.0195Gamma4.72Leverage Ratio-31.5406Theta0.0000Rho4.26Eff Leverage0.0007Vega
Intraday
- 5D
- 1D
News
Twist Bioscience Launches MGF Product, Stock Climbs 10%
Express News | Twist Bioscience Shares Are Trading Higher After the Company Announced the Launch of Twist Multiplexed Gene Fragments
Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Multiplexed Gene Fragments (MGFs), pools of directly synthesized double-stranded DNA (dsDNA) up to 500 base pairs in length with no limit on sequence number to enable high throughput screening applications.
Cathie Wood's Ark Invest Purchases Over $30M of Shopify Shares Amid Q1 Numbers-Driven Plunge; Adds Reddit Shares To Kitty — Offloads Coinbase Stock As Bitcoin Declines
On Wednesday, Cathie Wood's Ark Invest made some significant trades. The most prominent among these were the purchases of Shopify Inc (NYSE:SHOP) and Reddit Inc (NYSE:RDDT), and the selling off of Coi
Express News | Twist Bioscience Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) ("Twist" or the "Company"), a company enabling customers
Comments
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
4
Twist Bioscience's P/S ratio remains lower due to sub-par revenue outlook, indicating investor expectation of limited future growth. Shareholder pessimism around future revenue growth contributes to this lower ratio.
Twist Bioscience's optimistic cash runway and manageable burn rate are noteworthy despite the need for vigilance as the firm grows. Its market cap also points to easy fundraising potential.
Despite Twist Bioscience's unprofitability, rapid revenue growth indicates positive prospects. However, persistent share price decline hints at capital raising issues. Investors should assess the firm's balance sheet, market conditions and specific risks.
$Twist Bioscience(TWST.US$ Twist Bioscience Announced An Antibody Discovery, Option And License Agreement With Bayer Of Up To $188M. Bayer Will Have The Option To License Antibodies Discovered Under The Collaboration
Read more